CXCR4 antagonism restores dendritic cell migration and activation in a WHIM syndrome mouse model
Preprint
Abstract
WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome is a primary immunodeficiency caused by gain-of-function in CXCR4 chemokine receptor (CXCR4 GOF ) in response to its chemokine ligand CXCL12. The patients suffering from this syndrome display lymphopenia and neutropenia, and most of them show exacerbated susceptibility to human papillomavirus pathogenesis. In a mouse model harboring a WHIM-associated CXCR4 mutation and expressing HPV16 oncoproteins in keratinocytes, we previously reported reduced circulating plasmacytoid dendritic cells (pDCs), mirroring patients’ blood, and impaired dendritic cell (DC) trafficking from the skin to lymphoid organs, with the few migrating DCs displaying an overactivated phenotype. Given the promising results of CXCR4-targeted therapies in WHIM patients, we investigated whether and how the orally available CXCR4-specific antagonist, X4-136, affects DC localization, activation, and trafficking at the subset level, as well as skin immune landscape. CXCR4 GOF inhibition corrected defects in circulating myeloid cells and pDCs, as well as in lymph node-resident DCs. Furthermore, it rescued skin DC migration to lymph nodes in WHIM mice, in a context- and subset-dependent manner, by promoting their activation and relocation within the dermis. Taken together, these findings indicate that inhibiting CXCR4 GOF may restore skin immunity in WHIM syndrome by rescuing DC counts and functions. Key points: CXC R4 gain-of-function inhibition promotes subset-selective dermal dendritic cell migration to lymph nodes in a WHIM syndrome mouse model. Inhibiting CXCR4 corrects migratory WHIM dendritic cell hyperactivation with subset-specific effects tied to the inflammatory context.Keywords
Funding Information
- H2020-MSCA (ONCORNET 2.0 (ONCOgenic Receptor Network of Excellence and Training 2.0) PhD training program (H2020-MSCA grant agreement 860229))
- Agence Nationale de la Recherche (ANR-11-IDEX-0003)
- Agence Nationale de la Recherche (ANR-11-INBS-0010)
- Agence Nationale de la Recherche (ANR-21-ESRE-0035)
- Agence Nationale de la Recherche (ANR-24-INBS-0012)
This publication has 62 references indexed in Scilit:
- Inflammation switches the chemoattractant requirements for naive lymphocyte entry into lymph nodesCell, 2024
- FLT3L governs the development of partially overlapping hematopoietic lineages in humans and miceCell, 2024
- Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult PatientsJournal of Clinical Immunology, 2022
- The Oral CXCR4 Inhibitor X4-136 Improves Tumor Control and Reduces Toxicity in Cervical Cancer Treated With Radiation Therapy and Concurrent ChemotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Humans with inherited T cell CD28 deficiency are susceptible to skin papillomaviruses but are otherwise healthyCell, 2021
- WHIM Syndrome: from Pathogenesis Towards Personalized Medicine and CureJournal of Clinical Immunology, 2019
- RUNX2 Mediates Plasmacytoid Dendritic Cell Egress from the Bone Marrow and Controls Viral ImmunityCell Reports, 2016
- Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell InteractionsCell, 2015
- CXCR4 antagonist AMD3100 redistributes leukocytes from primary immune organs to secondary immune organs, lung, and blood in miceEuropean Journal of Immunology, 2015
- Chromothriptic Cure of WHIM SyndromeCell, 2015